

# Juraj Culman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6807600/publications.pdf>

Version: 2024-02-01

29  
papers

1,585  
citations

394421

19  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. <i>FASEB Journal</i> , 2005, 19, 1-25.	0.5	234
2	Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. <i>FASEB Journal</i> , 2006, 20, 1162-1175.	0.5	175
3	Blockade of Central Angiotensin AT <sub>1</sub> Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats. <i>Stroke</i> , 1999, 30, 2391-2399.	2.0	169
4	Chronic Treatment With a Low Dose of Lithium Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death. <i>Stroke</i> , 2003, 34, 1287-1292.	2.0	153
5	PPAR- $\delta$ : therapeutic target for ischemic stroke. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 244-249.	8.7	144
6	The intracerebral application of the PPAR $\delta$ -ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. <i>European Journal of Neuroscience</i> , 2005, 22, 278-282.	2.6	102
7	Sustained Blockade of Brain AT1 Receptors before and after Focal Cerebral Ischemia Alleviates Neurologic Deficits and Reduces Neuronal Injury, Apoptosis, and Inflammatory Responses in the Rat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 536-547.	4.3	81
8	Angiotensin Receptors in the Brain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995, 77, 306-315.	0.0	52
9	Effect of repetitive icv injections of ANG II on c-Fos and AT1-receptor expression in the rat brain. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 280, R1095-R1104.	1.8	46
10	Peroxisome-proliferator-activated receptors $\delta$ and peroxisome-proliferator-activated receptors $\gamma$ and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. <i>Journal of Hypertension</i> , 2010, 28, 1488-1497.	0.5	46
11	Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. <i>Journal of Neurochemistry</i> , 2005, 94, 1395-1401.	3.9	42
12	The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. <i>Molecular and Cellular Neurosciences</i> , 2012, 49, 300-310.	2.2	42
13	Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. <i>Journal of Hypertension</i> , 2007, 25, 187-196.	0.5	41
14	Peroxisome proliferator-activated receptors $\delta$ (PPAR $\delta$ ) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. <i>European Journal of Neuroscience</i> , 2008, 28, 1786-1794.	2.6	41
15	Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK <sub>1</sub> and NK <sub>2</sub> receptors in the rat. <i>British Journal of Pharmacology</i> , 1992, 107, 750-755.	5.4	38
16	Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial. <i>Experimental Neurology</i> , 2012, 238, 243-253.	4.1	38
17	Effects of the tachykinin NK <sub>1</sub> receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B. <i>British Journal of Pharmacology</i> , 1995, 114, 1310-1316.	5.4	29
18	Oxytocin Pathways Mediate the Cardiovascular and Behavioral Responses to Substance P in the Rat Brain. <i>Hypertension</i> , 1998, 31, 480-486.	2.7	26

#	ARTICLE	IF	CITATIONS
19	Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors. <i>Brain Research</i> , 1993, 625, 75-83.	2.2	23
20	Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways. <i>Journal of Molecular Medicine</i> , 2021, 99, 1073-1083.	3.9	16
21	Activation of intracellular angiotensin AT2 receptors induces rapid cell death in human uterine leiomyosarcoma cells. <i>Clinical Science</i> , 2015, 128, 567-578.	4.3	12
22	Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 949-959.	3.0	9
23	Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor $\beta$ -independent mechanism. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 37-48.	3.0	8
24	Antisense Oligonucleotides in the Study of Central Mechanisms of the Cardiovascular Regulation. <i>Experimental Physiology</i> , 2000, 85, 757-767.	2.0	6
25	Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?. <i>Neuropharmacology</i> , 2012, 63, 958-965.	4.1	6
26	In vivo SPECT imaging of [123I]-labeled pentamidine pro-drugs for the treatment of human African trypanosomiasis, pharmacokinetics, and bioavailability studies in rats. <i>International Journal of Pharmaceutics</i> , 2014, 477, 167-175.	5.2	2
27	Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 939-951.	3.0	2
28	The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 1271-1281.	3.3	1
29	Antisense oligonucleotides in the study of central mechanisms of the cardiovascular regulation. <i>Experimental Physiology</i> , 2000, 85, 757-767.	2.0	1